Authors' response to a letter to the editor re: Sentinel node biopsy for early-stage melanoma [5]

Annals of Surgery

Volumn 245, Issue 5, 2007, Pages 828-829

  Morton, Donald L ^a   Cochran, Alistair J ^b   Thompson, John F ^c  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ANALYTICAL ERROR; DISEASE FREE SURVIVAL; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; LETTER; LYMPH NODE DISSECTION; LYMPHADENECTOMY; MELANOMA; METASTASIS; MICROMETASTASIS; MORBIDITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; SURVIVAL RATE;

HUMANS; MELANOMA; NEOPLASM STAGING; REPRODUCIBILITY OF RESULTS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 34247586648     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000261157.79250.16     Document Type: Letter

References (6)

1. Twomey P. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-1, an international multicenter trial. Ann Surg. 2007;245:156-157.
2. Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005;242:302-311.
3. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-1317.
4. Morton DL, Cochran AJ, Thompson JF. Sentinel-node biopsy in melanoma letter-. N Engl J Med. 2007;356:419-420.
5. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol. 2003;21:1404-1411.
6. Balch CM, Cascinelli N. Sentinel-node biopsy in melanoma letter-. N Engl J Med. 2007;356:420-421.